During the last three months, 8 analysts shared their evaluations of Neurocrine Biosciences NBIX, revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 3 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Neurocrine Biosciences and provided 12-month price targets. The average target is $151.88, accompanied by a high estimate of $200.00 and a low estimate of $140.00. Surpassing the previous average price target of $141.00, the current average has increased by 7.72%.
Exploring Analyst Ratings: An In-Depth Overview
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jay Olson | Oppenheimer | Raises | Outperform | $200.00 | $170.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $148.00 | $154.00 |
| David Hoang | Citigroup | Lowers | Neutral | $140.00 | $141.00 |
| Uy Ear | Mizuho | Raises | Neutral | $140.00 | $116.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $140.00 | $127.00 |
| Chris Shibutani | Goldman Sachs | Raises | Buy | $153.00 | $134.00 |
| Carter Gould | Barclays | Raises | Overweight | $150.00 | $145.00 |
| Paul Matteis | Stifel | Raises | Buy | $144.00 | $141.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Neurocrine Biosciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
All You Need to Know About Neurocrine Biosciences
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Neurocrine Biosciences: Delving into Financials
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Neurocrine Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.05% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Neurocrine Biosciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 28.67%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 6.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Neurocrine Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 4.84%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
